AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receives College of American Pathologists Accreditation for U.S. Laboratory
- AnPac Bio’s clinical laboratories are located in the U.S. and China, with a total of 142 patents issued as of March 2021
- Cancer Differentiation Analysis (“CDA”) technology is AnPac Bio’s approach to early cancer detection and screening technology, with over 200,000 samples and cases to serve as a way of approaching cancer screening
- Company’s ownership percentage in subsidiary AnPai (Shanghai) Healthcare Management Consultant Co. Ltd. has increased from 20% to 60%, following rigorous regulatory assessments and audits
With a focus on early cancer screening and detection, biotechnology company AnPac Bio-Medical Science (NASDAQ: ANPC) recently announced that its U.S. laboratory has received accreditation from the College of American Pathologists (“CAP”). The U.S. federal government recognizes the CAP Laboratory Accreditation Program as equivalent to or more stringent than the government’s inspection program for laboratories. The accreditation from CAP is considered the gold standard for laboratories of this nature (https://nnw.fm/UhtfA).
AnPac Bio has clinical laboratories in the U.S. and China, totaling 142 patents issued as of March 2021. The company’s approach for detecting cancer and precancerous diseases is called Cancer Differentiation Analysis (“CDA”) and uses biophysical properties found in the blood to discover changing micro-environments towards cancerous micro-environments before the tumors are even formed. CDA technology uses an assessment of biophysical properties in the blood, and CDA platform combines CDA technology with other tests such as biomarkers. CDA is also helpful in potentially predicting multiple cancer types, through a blood test, which is a highly competitive price point.
AnPac Bio’s CDA is powered by a database completed with over 200,000 samples and cases to serve as a new way of approaching disease and cancer screening. The company is an early thought leader and developer of multi-cancer ideas and technology, having begun its patent applications and IP in 2010, with the initial cancer detection test offering being able to detect 16 types of cancer announced by 2014.
In addition to its CAP accreditation in the U.S., AnPac Bio has increased its ownership percentage in subsidiary AnPai (Shanghai) Healthcare Management Consultant Co., Ltd., as approved by the audit committee and board of directors. The ownership increase from 20% to 60% follows a required due diligence process of financial and legal audits, in addition to appraisals by a qualified appraiser (https://nnw.fm/hbJR0).
“AnPac Bio is excited to have completed this important step. We are able to successfully incorporate with AnPai’s wide diversity of customers and high revenue growth through this transaction,” Dr. Chris Yu, CEO and Chairman of AnPac Bio said, commenting on the ownership share acquisition. “In the future, we will achieve faster and greater progress and development in the diversity of customers and the professionalism of our services, as well as projected sustainable revenue growth through our greater share ownership. We hope that customers will benefit from AnPac Bio’s CDA technology.”
AnPac Bio’s CDA technology addresses numerous goals, which include innovating the cancer screening industry, detecting early signs of cancer in the body, identifying up to 26 different types of cancers, providing multi-level/multi-parameter analysis, proving the efficacy of the CDA technology through the 200,000 samples, and using human blood for the means of identifying biophysical properties in conjunction with cancer occurrences.
The technology has positioned AnPac Bio as a leader on the cancer detection and screening market, with the largest on-going multi-cancer follow-up study in the world, an expanding market expected to reach $249.6 billion by 2026, growing at a CAGR of 7% during the forecast period. The rising incidence of cancer is triggering a higher demand for available and effective screenings and testing necessary for monitoring disease progression and increasing preventative measures.
For more information, visit the company’s website at www.AnPacBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://nnw.fm/ANPC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- AnPac Bio’s clinical laboratories are located in the U.S. and China, with a total of 142 patents issued as of March 2021
- Cancer Differentiation Analysis (“CDA”) technology is AnPac Bio’s approach to early cancer detection and screening technology, with over 200,000 samples and cases to serve as a way of approaching cancer screening
- Company’s ownership percentage in subsidiary AnPai (Shanghai) Healthcare Management Consultant Co. Ltd. has increased from 20% to 60%, following rigorous regulatory assessments and audits
With a focus on early cancer screening and detection, biotechnology company AnPac Bio-Medical Science (NASDAQ: ANPC) recently announced that its U.S. laboratory has received accreditation from the College of American Pathologists (“CAP”). The U.S. federal government recognizes the CAP Laboratory Accreditation Program as equivalent to or more stringent than the government’s inspection program for laboratories. The accreditation from CAP is considered the gold standard for laboratories of this nature (https://nnw.fm/UhtfA).
AnPac Bio has clinical laboratories in the U.S. and China, totaling 142 patents issued as of March 2021. The company’s approach for detecting cancer and precancerous diseases is called Cancer Differentiation Analysis (“CDA”) and uses biophysical properties found in the blood to discover changing micro-environments towards cancerous micro-environments before the tumors are even formed. CDA technology uses an assessment of biophysical properties in the blood, and CDA platform combines CDA technology with other tests such as biomarkers. CDA is also helpful in potentially predicting multiple cancer types, through a blood test, which is a highly competitive price point.
AnPac Bio’s CDA is powered by a database completed with over 200,000 samples and cases to serve as a new way of approaching disease and cancer screening. The company is an early thought leader and developer of multi-cancer ideas and technology, having begun its patent applications and IP in 2010, with the initial cancer detection test offering being able to detect 16 types of cancer announced by 2014.
In addition to its CAP accreditation in the U.S., AnPac Bio has increased its ownership percentage in subsidiary AnPai (Shanghai) Healthcare Management Consultant Co., Ltd., as approved by the audit committee and board of directors. The ownership increase from 20% to 60% follows a required due diligence process of financial and legal audits, in addition to appraisals by a qualified appraiser (https://nnw.fm/hbJR0).
“AnPac Bio is excited to have completed this important step. We are able to successfully incorporate with AnPai’s wide diversity of customers and high revenue growth through this transaction,” Dr. Chris Yu, CEO and Chairman of AnPac Bio said, commenting on the ownership share acquisition. “In the future, we will achieve faster and greater progress and development in the diversity of customers and the professionalism of our services, as well as projected sustainable revenue growth through our greater share ownership. We hope that customers will benefit from AnPac Bio’s CDA technology.”
AnPac Bio’s CDA technology addresses numerous goals, which include innovating the cancer screening industry, detecting early signs of cancer in the body, identifying up to 26 different types of cancers, providing multi-level/multi-parameter analysis, proving the efficacy of the CDA technology through the 200,000 samples, and using human blood for the means of identifying biophysical properties in conjunction with cancer occurrences.
The technology has positioned AnPac Bio as a leader on the cancer detection and screening market, with the largest on-going multi-cancer follow-up study in the world, an expanding market expected to reach $249.6 billion by 2026, growing at a CAGR of 7% during the forecast period. The rising incidence of cancer is triggering a higher demand for available and effective screenings and testing necessary for monitoring disease progression and increasing preventative measures.
For more information, visit the company’s website at www.AnPacBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://nnw.fm/ANPC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
